Fractyl’s Revita DMR System commercially available in Germany
Fractyl Health has announced the commercial availability of its Revita DMR System in Germany, an endoscopic procedural therapy that is...
top of page
Browse by category
Search
Fractyl initiates Erase T2DM task force to establish root cause mechanisms underlying T2DM
Fractyl Health has created the Erase T2D task force, an academic-industry scientific partnership charged with advancing research on the...
Fractyl Health reports latest Revita DMR outcomes for T2DM
New data from Fractyl Health’s Revita-1 and Revita-2 studies presented at Digestive Disease Week 2022 builds on this earlier evidence to...
Two-year Revita DMR outcomes show durability of procedure in diabetics
Two-year durability data from the REVITA-1 clinical study, conducted at centres in Europe and South America, revealed that HbA1c was...
Fractyl’s pioneering Metabolic Balance Model identifies new model of intestine’s role in metabolism
Fractyl Health has announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesises...
Fractyl gains US$100 million financing to expand clinical development programs for T2DM
Fractyl Health (formerly Fractyl Laboratories) has closed a US$100 million Series F financing to support multiple late-stage clinical...
Revita DMR granted FDA Breakthrough Device Designation for T2DM
Fractyl Laboratories has announced that the FDA has granted Breakthrough Device Designation for Revita DMR (duodenal mucosal resurfacing)...
First patient enrolled in pivotal REVITA-T2Di study for T2DM
Fractyl Laboratories has announced the enrolment of the first patient in a pivotal clinical trial of Revita DMR (duodenal mucosal...
INSPIRE: Revita DMR plus GLP-1RA shows durable insulin-free glycaemic control
Outcomes form the investigator-initiated INSPIRE clinical trial, conducted in collaboration with Fractyl, have demonstrate that a...
Browse by tag
bottom of page